Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

Temporary Change in Preferred Status for the Neuropathic Pain Drug Class Effective April 3, 2023

Last updated on

Effective April 3, 2023, the Texas Health and Human Services Commission (HHSC) has temporarily removed the non-preferred status from the generic product lidocaine 5% patch on the preferred drug list (PDL). (The lidocaine 5% patch is in the neuropathic pain drug class.) This temporary removal is in response to the shortage of the preferred brand name product Lidoderm 5% patch, which was discontinued by the manufacturer.

Note: The preferred status of the brand name product Lidoderm (NDC 63481-0687-06) will not change so that any available existing stock can be used.

Effective April 3, 2023, the following generic drugs reflect these changes in the daily formulary file for Medicaid managed care organizations (MCOs):

National Drug Code (NDC)

Generic Drug Name


Lidocaine 5% patch


Lidocaine 5% patch


Lidocaine 5% patch


Lidocaine 5% patch


Lidocaine 5% patch


Lidocaine 5% patch

These changes allow providers to prescribe the generic lidocaine patches without a PDL prior authorization and continue accessing necessary medication for clients. This is a temporary change until HHSC can further assess the availability of any alternative brand name products in the neuropathic pain PDL class. HHSC will provide more information about future PDL status changes when it becomes available.

Email with comments or any questions.